Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
- PMID: 34713870
- DOI: 10.1358/dot.2021.57.10.3313852
Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
Abstract
Aberrations in oncogene RET (rearranged during transfection) have been found to be the cause of different kinds of malignancies, especially in lung and thyroid cancers. Targeted therapy of RET-altered cancers using multi-kinase inhibitors (MKIs) has demonstrated limited clinical efficacy due to off-target toxicity. In May 2020, the U.S. Food and Drug Administration (FDA) approved a novel specific RET inhibitor for use in some subtypes of lung and thyroid cancers with RET alterations. In this review, we summarize the mechanism of action, pharmaceutical properties and clinical data of selpercatinib, and share some of our perspectives.
Keywords: Antitumor drugs; Lung cancer; Rearranged during transfection (RET) gene mutations or fusions; Selpercatinib; Solid tumors therapy; Targeted therapy; Thyroid cancer; Tyrosine kinase inhibitors.
Copyright 2021 Clarivate Analytics.
Similar articles
-
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15. Cancer Discov. 2018. PMID: 29657135
-
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.Clin Cancer Res. 2021 Apr 15;27(8):2130-2135. doi: 10.1158/1078-0432.CCR-20-3558. Epub 2020 Nov 25. Clin Cancer Res. 2021. PMID: 33239432
-
Selpercatinib: First Approval.Drugs. 2020 Jul;80(11):1119-1124. doi: 10.1007/s40265-020-01343-7. Drugs. 2020. PMID: 32557397 Free PMC article. Review.
-
Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1117-1122. doi: 10.1080/14737140.2023.2267754. Epub 2023 Oct 27. Expert Rev Anticancer Ther. 2023. PMID: 37795873 Review.
-
Precious Gene: The Application of RET-Altered Inhibitors.Molecules. 2022 Dec 13;27(24):8839. doi: 10.3390/molecules27248839. Molecules. 2022. PMID: 36557971 Free PMC article. Review.
Cited by
-
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA.ESMO Open. 2021 Feb;6(1):100041. doi: 10.1016/j.esmoop.2020.100041. Epub 2021 Jan 18. ESMO Open. 2021. PMID: 33477006 Free PMC article. No abstract available.
-
A comprehensive overview of the relationship between RET gene and tumor occurrence.Front Oncol. 2023 Feb 14;13:1090757. doi: 10.3389/fonc.2023.1090757. eCollection 2023. Front Oncol. 2023. PMID: 36865807 Free PMC article. Review.
-
Targeted therapeutic options in early and metastatic NSCLC-overview.Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024. Pathol Oncol Res. 2024. PMID: 38605928 Free PMC article. Review.
-
Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221148802. doi: 10.1177/15330338221148802. Technol Cancer Res Treat. 2023. PMID: 36628459 Free PMC article. Review.
-
Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.BMC Cancer. 2021 Jan 5;21(1):28. doi: 10.1186/s12885-020-07714-3. BMC Cancer. 2021. PMID: 33402119 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
